FDA approves Roche's Wilserdly with everolimus for ESR1-mutated advanced breast cancer

Roche's oral selective oestrogen receptor degrader Wilserdly has received FDA approval alongside everolimus for eligible patients with ESR1-mutated advanced breast cancer, supported by Phase III evidence of reduced disease progression risk.
The US Food and Drug Administration approved Wilserdly (giredestrant) in combination with everolimus on 16 November 2026 for adults with ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer who meet the specified prior-treatment requirements, with mutation status established using an FDA-authorised test.
In the Phase III evERA study, the combination demonstrated a 62% reduction in the risk of disease progression or death compared with standard endocrine therapy plus everolimus in the ESR1-mutated population, while the FDA also authorised FoundationOne Liquid CDx as a companion diagnostic; the decision concerns advanced disease and is separate from the adjuvant application still under review.
Field | Content |
Article Type | Approvals |
Company | Roche |
US Company | Genentech |
Product Brand Name | Wilserdly |
Active Ingredient | Giredestrant |
Drug Classification | Oral selective oestrogen receptor degrader |
Drug Class Abbreviation | SERD |
Combination Medicine | Everolimus |
Regulatory Authority | US Food and Drug Administration |
Approval Date | 16 November 2026 |
Regulatory Decision | FDA marketing approval |
Geographic Scope | United States |
Therapeutic Area | Oncology |
Cancer Type | Breast cancer |
Hormone Receptor Status | Oestrogen receptor-positive |
HER2 Status | HER2-negative |
Required Molecular Alteration | ESR1 mutation |
Approved Disease Setting | Locally advanced or metastatic breast cancer |
Patient Population | Eligible adults meeting the authorised prior-treatment and molecular-testing requirements |
Treatment Regimen | Giredestrant plus everolimus |
Supporting Clinical Trial | evERA |
Clinical Trial Phase | Phase III |
Key Efficacy Measure | Progression-free survival |
Reported Relative Risk Reduction | 62% reduction in risk of disease progression or death |
Comparator | Standard endocrine therapy plus everolimus |
Companion Diagnostic | FoundationOne Liquid CDx |
Companion Diagnostic Status | FDA-authorised |
Separate Regulatory Programme | Adjuvant breast cancer application |
Adjuvant Application Status | Under review according to supplied summary |
What Happened | The FDA authorised giredestrant with everolimus for a molecularly defined advanced breast cancer population. |
Why It Matters | The approval introduces an additional targeted endocrine treatment option for patients with ESR1-mutated advanced breast cancer. |
Clinical Significance | The pivotal study reported a substantial relative reduction in progression or death risk compared with the control regimen. |
Regulatory Significance | The decision combines a new medicine approval with companion diagnostic authorisation. |
Clinical Interpretation | The 62% figure is a relative risk reduction and should not be described as an absolute survival improvement. |
Key Takeaway | Wilserdly plus everolimus is FDA-approved for eligible patients with ESR1-mutated advanced breast cancer. |
What to Watch | US treatment uptake, molecular testing access, safety data, reimbursement and the separate adjuvant regulatory decision. |
Primary Source | US Food and Drug Administration |
Primary Source URL | https://www.fda.gov/drugs/cancer-approvals/fda-approves-giredestrant-combination-everolimus-er-positive-her2-negative-esr1-mutated-locally |
Relevant Date | 16 November 2026 |
Discover how nuaxia can support your next medical education initiative:
Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector
Contact us on: support@nuaxia.com

Comments